Lower Targets Amid Insider Selling
Major Wall Street Analysts Lower Price Targets While Maintaining Ratings Across Three Companies
Anonymous
Analysts maintained their ratings on three companies while lowering price targets. Baird kept H.B. Fuller at Outperform but cut its target from $75 to $65 on Sept. 25, 2026, and maintained a Neutral rating on Cognex while reducing its target from $78 to $70. Needham maintained a Buy rating on ACADIA Pharmaceuticals on Oct. 24, 2023, but lowered its target from $41 to $35. The reports also noted recent insider selling at all three companies, though these analyst updates indicate different outlooks: continued optimism for H.B. Fuller and ACADIA, and a more cautious stance on Cognex.
Key Points
1
The articles quantify recent insider selling at each company: $593,356 at H.B. Fuller, $1,317,833 at ACADIA Pharmaceuticals, and $1,597,820 at Cognex over the stated three-month periods.
2
GuruFocus put H.B. Fuller’s GF Value at $64.99, describing the shares as 23.1% undervalued relative to the article’s cited market price of $50.00; its trailing P/E was 14.85, below its five-year median of 24.37.
3
ACADIA develops treatments for central nervous system disorders and rare diseases; the article identifies NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome among its products.
4
GuruFocus assessed Cognex as trading at an 11.0% premium to its $53.15 GF Value; its P/E of 57.09 was also above its five-year median of 53.35.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
26
Articles
23
Reach
49
A
AnonymousAuthor
